Sensitivity to treatment and score bands of the Infants and Toddlers Dermatology Quality of Life questionnaire.
COVID-19, coronavirus disease of 2019
DLQI, Dermatology Life Quality Index
HRQoL, health related quality of life
InToDermQoL, Infants and Toddlers Dermatology Quality of Life
M, mean
MID, minimally important difference
SCORAD, scoring of atopic dermatitis
SD, standard deviation
patient-reported outcome measures
pediatric dermatology
quality of life
severity banding
treatment
Journal
JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
accepted:
20
11
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
The Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire is the first dermatology-specific proxy health related QoL instrument for children from birth to 4 years. Score meaning bands and the sensitivity to successful therapeutic intervention are important to interpret the clinical meaning of an instrument. The aim of the present study was to check the sensitivity to successful therapeutic intervention and establish score bands of the InToDermQoL questionnaire. Parents or grandparents of 424 children with skin diseases from Spain, Malta, Croatia, Romania, Greece, and Ukraine filled in national language versions of the InToDermQoL questionnaire. Disease severity of children with atopic dermatitis was assessed by SCORAD (Scoring atopic dermatitis). Cohen's d was used to assess the responsiveness of the instrument. The mean total InToDermQoL scores significantly decreased after treatment. Severity grading of the SCORAD scores gave stratification of the InToDermQoL severity grades based on 95% confidence intervals. Scores below a calculated minimal important difference of 2 corresponded to no effect on patient's health related QoL. Score banding may be slightly different across patient population and study context. All 3 age-specific versions of the InToDermQoL questionnaire showed sensitivity to treatment. Score bands for the InToDermQoL questionnaire have been established.
Sections du résumé
Background
UNASSIGNED
The Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire is the first dermatology-specific proxy health related QoL instrument for children from birth to 4 years. Score meaning bands and the sensitivity to successful therapeutic intervention are important to interpret the clinical meaning of an instrument.
Objective
UNASSIGNED
The aim of the present study was to check the sensitivity to successful therapeutic intervention and establish score bands of the InToDermQoL questionnaire.
Methods
UNASSIGNED
Parents or grandparents of 424 children with skin diseases from Spain, Malta, Croatia, Romania, Greece, and Ukraine filled in national language versions of the InToDermQoL questionnaire. Disease severity of children with atopic dermatitis was assessed by SCORAD (Scoring atopic dermatitis). Cohen's d was used to assess the responsiveness of the instrument.
Results
UNASSIGNED
The mean total InToDermQoL scores significantly decreased after treatment. Severity grading of the SCORAD scores gave stratification of the InToDermQoL severity grades based on 95% confidence intervals. Scores below a calculated minimal important difference of 2 corresponded to no effect on patient's health related QoL.
Limitations
UNASSIGNED
Score banding may be slightly different across patient population and study context.
Conclusion
UNASSIGNED
All 3 age-specific versions of the InToDermQoL questionnaire showed sensitivity to treatment. Score bands for the InToDermQoL questionnaire have been established.
Identifiants
pubmed: 36688100
doi: 10.1016/j.jdin.2022.11.009
pii: S2666-3287(22)00157-2
pmc: PMC9850170
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-67Informations de copyright
© 2022 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.
Déclaration de conflit d'intérêts
None disclosed.
Références
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):424-431
pubmed: 27684717
Acta Derm Venereol. 2017 Apr 6;97(4):546-547
pubmed: 28303279
Dermatology. 2019;235(3):167-174
pubmed: 30928986
Dermatol Ther (Heidelb). 2021 Dec;11(6):2017-2026
pubmed: 34562266
Pediatr Dermatol. 2009 Jan-Feb;26(1):99-100
pubmed: 19250422
Dermatology. 1997;195(1):10-9
pubmed: 9267730
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):612-617
pubmed: 30422350
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e123-e124
pubmed: 31705674
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
J Clin Aesthet Dermatol. 2016 Aug;9(8):19-24
pubmed: 27672414
G Ital Dermatol Venereol. 2013 Jun;148(3):277-85
pubmed: 23670064
Dermatol Ther. 2020 Nov;33(6):e14128
pubmed: 32761748
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1221-4
pubmed: 24981284
J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1045-60
pubmed: 22805051
J Eur Acad Dermatol Venereol. 2016 May;30(5):729-47
pubmed: 27004560
J Eur Acad Dermatol Venereol. 2018 May;32(5):e181-e182
pubmed: 29135046
J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1483-4
pubmed: 21155896
J Invest Dermatol. 2005 Oct;125(4):659-64
pubmed: 16185263
Pharmacoeconomics. 1999 Feb;15(2):141-55
pubmed: 10351188
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1254-1259
pubmed: 28370433
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1666-1671
pubmed: 32498128
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2288-2294
pubmed: 30169902
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1405-1411
pubmed: 30767284
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):20-23
pubmed: 34687091
Dermatology. 1993;186(1):23-31
pubmed: 8435513